Ads
related to: abraxane paclitaxel
Search results
Results From The WOW.Com Content Network
Protein-bound paclitaxel was developed by VivoRx which became Abraxis BioScience as the first in its class of drugs to use the nanoparticle albumin bound (nab) technology platform. [14] In 2010, Abraxis was acquired by Celgene, which now markets Abraxane. [15] Total revenue from the sales of Abraxane for 2009 were $314.5 million. [16]
Albumin-bound paclitaxel (brand name Abraxane, also called nab-paclitaxel) is an alternative formulation where paclitaxel is bound to albumin nanoparticles. Much of the clinical toxicity of paclitaxel is associated with the solvent Cremophor EL in which it is dissolved for delivery.
ABRAXANE ® for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) is indicated for the treatment of breast cancer after failure of combination ...
Patrick Soon-Shiong (born July 29, 1952) is a South African and American businessman, investor, medical researcher, and transplant surgeon. He is the inventor of the drug Abraxane, which is used for lung, breast, and pancreatic cancer.
ABRAXANE is an albumin-bound form of paclitaxel that is manufactured using patented nab ® technology. ABRAXANE is formulated with albumin, a human protein, and is free of solvents.
FDA Approves ABRAXANE ® for the First-Line Treatment of Advanced Non-Small Cell Lung Cancer Approval Based on Significantly Improved Overall Response Rates in all Patients Regardless of Histology ...
For patients whose cancer progressed after receiving second-line Gemcitabine-Abraxane chemotherapy (n=7), findings show a median OS of 23.0 months since the initiation of Gemcitabine-Abraxane, and a median OS of 9.0 months since being treated with Alpha DaRT, with three of seven treated patients still alive, compared to historical studies
ABRAXANE Meets Primary Endpoint of Progression-Free Survival in Phase III Chemotherapy-Naïve Metastatic Melanoma Study BOUDRY, Switzerland--(BUSINESS WIRE)-- Celgene International Sàrl, a ...